ArchivesPress Releases Archives Media Inquiries In the News YearAll20242023202220212020201920182017201620152014CategoryAllBrandsGenericsTechnologyPartners November 19, 2024Tris Pharma Secures Additional ex-US Approvals to Expand Global Availability of Quillivant XR and QuilliChew ER for the Treatment of Attention Deficit Hyperactivity Disorder October 1, 2024Tris Pharma’s Once-Daily ADHD Medication, ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, Now Available in the United States September 17, 2024Tris Pharma Promotes Manesh Naidu to Chief Commercial Officer September 3, 2024Findings Presented at PAINWeek 2024 Demonstrate Tris Pharma’s Investigational, First-in-Class Therapy Cebranopadol Provides Potent, Prolonged Pain Relief with Improved Safety Over Oxycodone August 21, 2024Tris Pharma Initiates ALLEVIATE-1 and ALLEVIATE-2, Pivotal Phase 3 Trials Investigating Cebranopadol, a First-in-Class Compound with a Novel Mechanism of Action to Treat Pain August 6, 2024Tris Pharma Presents New Clinical Data Demonstrating Robust Safety and Efficacy of Investigational, First-in-Class Therapy Cebranopadol for Treatment of Pain July 30, 2024Tris Pharma to Present New Safety Data for First-In-Class Investigational Pain Therapy and Host Symposium at the International Association for the Study of Pain (IASP) 2024 World Congress on Pain June 12, 2024Cranbury Pharmaceuticals Receives U.S. FDA Approval for First Generic Version of Emflaza® Oral Suspension (deflazacort) for Duchenne Muscular Dystrophy May 29, 2024Tris Pharma Receives U.S. FDA Approval for Once-Daily ONYDA XR (clonidine hydrochloride) Extended-Release Oral Suspension, the First-and-Only Liquid Non-Stimulant ADHD Medication April 16, 2024Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD February 7, 2024Tris Pharma Appoints Michael Magee as Vice President, Quality & Compliance January 22, 2024Tris Pharma Appoints Franchesca Fowler to Chief Compliance Officer and Vice President, General Counsel October 30, 2023Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL® XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder September 25, 2023Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder September 5, 2023Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference August 28, 2023Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH’s National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder May 2, 2023Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline December 13, 2022Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Significantly Less Potential for Abuse Versus Tramadol and Oxycodone December 7, 2022Tris Pharma Announces Acquisition of New, Late-Stage Drug Candidate for Pain December 1, 2022Tris Pharma and Pediatrix Therapeutics Announce Expansion of Partnership to Commercialize Tris’s ADHD Portfolio and Pipeline Products in China October 19, 2022Tris Pharma Announces Continued Supply and Availability of DYANAVEL® XR (amphetamine) Tablets and Oral Suspension for ADHD Despite Adderall shortage August 18, 2022Tris Pharma Announces US District Court Upholds Validity of QuilliChew ER® Patents; Rules Teva Infringes Tris Patents August 16, 2022Tris Pharma Announces Availability of New DYANAVEL® XR (amphetamine) Tablets for ADHD July 27, 2022Tris Pharma Announces Development of a Very Low Sodium and Once-Nightly Oxybate Formulation July 22, 2022Tris Pharma Announces Publication of Study Results Highlighting the Efficacy and Safety of DYANAVEL® XR (amphetamine) Tablets for the Treatment of the Symptoms of ADHD in Adults July 20, 2022Tris Pharma announces U.S. Court of Appeals for the Federal Circuit Affirms Validity of Quillivant XR® Patents; Rules Teva Infringes Tris Patents November 5, 2021Tris Pharma Announces FDA Approval of DYANAVEL® XR (amphetamine) Once-Daily Extended-Release Oral Tablets, CII, for ADHD October 7, 2021Tris Pharma® Hires Seasoned Business Development Executive Anthony Amato joins as Executive Vice President Business Development – Generics Division April 29, 2021Tris Pharma® Announces Acquisition of Park Therapeutics – Pain Company with First-in-class, Phase III-Ready New Chemical Entity (NCE) February 22, 2021Tris Pharma and Athena Bioscience Announce Exclusive License Agreement to Commercialize Near-to-Market Long-Acting Antihypertensive Product in the U.S. January 28, 2021APSARD and Tris Pharma Announce the 2021 Tris Research Award in ADHD January 20, 2021Tris Pharma Presents Positive Results from Phase 3 Study of Amphetamine Extended-Release Tablet in Adults with ADHD January 15, 2021Tris Pharma to Debut Amphetamine Extended-Release Tablet Efficacy and Safety Data at the 2021 APSARD Annual Meeting December 18, 2020Tris Pharma Hires Seasoned Research & Development Executive December 8, 2020Tris Pharma and Neuraxpharm Group Announce Partnership to Commercialize Tris’ Quillivant XR and Quillichew ER in Europe December 1, 2020Tris announces US District Court Upholds Validity of Quillivant XR® Patents; Rules Teva Infringes Tris Patents November 17, 2020Tris Pharma and Medison Pharma Announce Exclusive License Agreement to Commercialize Tris’ Quillivant XR in Israel November 10, 2020Tris Pharma Launches New ADHD Portfolio Website for Patients and Caregivers October 22, 2020Tris Pharma to Present Amphetamine Extended-Release Tablet Data at the Research Pipeline Session of 2020 American Academy of Child and Adolescent Psychiatry Meeting October 6, 2020Tris Pharma Launches its Scientific Advisory Board September 17, 2020Tris Pharma Launches Redesigned Website for ADHD Healthcare Professionals July 9, 2020Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement to Commercialize Tris ADHD Products in Canada June 25, 2020Tris Pharma Launches New Corporate Website March 17, 2020Quillivant XR®, QuilliChew ER® and Dyanavel® XR are 100% Made in the U.S.A. and Remain Consistently Supplied During COVID-19 Pandemic January 17, 2020APSARD and Tris Pharma Announce the Inaugural Tris Research Award in ADHD November 7, 2019Tris Pharma to Present Two Posters for Amphetamine Extended-Release Tablet at the 2019 October 30, 2019Tris Pharma Adds Seasoned Attorney to its Senior Leadership Team September 4, 2019Tris Pharma Strengthens Its Branded Commercial Leadership Team August 14, 2019Tris Pharma Chief Medical Officer Elected to the American Psychiatric Association Assembly Executive Committee January 29, 2019Tris Pharma, Inc Expands Its Voluntary Nationwide Retail Recall of Ibuprofen Oral Suspension Drops, USP, 50 mg per 1.25 mL, Due to Higher Concentration of Ibuprofen January 28, 2019Information Related to the Voluntary Recall of Infants' Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL January 17, 2019Tris Pharma to Present Three Posters Covering Data on Dyanavel® XR and Tris’ LiquiXR® Technology at the 2019 APSARD Annual Meeting December 5, 2018Tris Pharma Issues Voluntary Nationwide Recall of Infants' Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen November 12, 2018Tris Pharma Presents Clinical Data for DYANAVEL® XR (amphetamine) at the 2018 Neuroscience Education Institute (NEI) Congress November 5, 2018Aytu BioScience Enters $3 Billion Cough and Cold Market and Expands Primary Care Portfolio, with Exclusive U.S. Licensing of Revenue-Generating, FDA-Approved Antitussive Tuzistra® XR October 24, 2018Tris Pharma Presents Results from Two Clinical Studies on Dyanavel® XR at the Largest Annual Meeting of Child and Adolescent Psychiatrists October 10, 2018Tris Pharma Announces Hiring of Chief Commercial Officer October 4, 2018Deerfield Provides $125 million Debt Financing to Tris Pharma September 25, 2018Tris Pharma Expands ADHD Portfolio with Acquisition of NextWave Pharmaceuticals August 27, 2018Tris Pharma Announces Hiring of New Vice President of Quality & Compliance February 9, 2017Tris Pharma’s Results from a Laboratory Classroom Study of DYANAVEL® XR in Children with ADHD Featured at APSARD December 20, 2016FDA accepts CCP-08 NDA for full review September 5, 2016FDA Accepts CCP-07 NDA for Full Review April 19, 2016Tris Pharma Announces the Launch of DYANAVEL™ XR (amphetamine) Extended-release Oral Suspension, CII for the Treatment of Children with ADHD December 16, 2015Tris Pharma Announces First Ever FDA-Approved Extended-Release Chewable Tablet December 7, 2015Pfizer Receives U.S. FDA Approval of New QuilliChew ER™ (methylphenidate hydrochloride) extended-release chewable tablets CII October 20, 2015Tris Pharma Receives FDA Approval of Dyanavel™ XR (amphetamine) CII as Once-Daily Liquid for Treatment of ADHD in Children October 1, 2015Tris Pharma Launches Generic Tussionex® as Par’s Rights Expire September 7, 2015Vernalis PLC launches Tuzistra™ XR (codeine polistirex and chlorpheniramine polistirex) for cough relief with 12-hour dosing August 13, 2015FSC Pediatrics Launches Karbinal™ ER (carbinoxamine maleate) For the Symptomatic Treatment of Seasonal and Perennial Allergic Rhinitis for Children June 29, 2015Tris Pharma and Pfizer Consumer Healthcare Enter Into Agreement to Commercialize 12-Hour Extended Release Dextromethorphan Cough Syrup under the Robitussin® Brand May 21, 2015Tris Pharma Announces the FDA Acceptance of NDA for Dyanavel™ XR May 1, 2015Vernalis and Tris Pharma receive FDA approval of NDA for Tuzistra™ XR September 15, 2014FDA accepts Tuzistra™ XR (CCP-01) NDA for full review August 27, 2014Tris Pharma Receives NJBIA Award for Excellence July 22, 2014Third Product in Vernalis’ Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept June 30, 2014Submission of Tuzistra™ XR (CCP-01) NDA to FDA April 1, 2014Second Product in Vernalis’ Cough Cold Pipeline Achieves Proof-of-Concept February 1, 2014Vernalis Announces Successful Completion of Second Pivotal Bioavailability Study with First Cough Cold Product, CCP-01 September 4, 2013Tris Pharma and FSC Laboratories Sign Definitive Commercialization Agreement for Karbinal™ ER (carbinoxamine maleate) Extended-Release Oral Suspension July 10, 2013Tris Pharma’s Generic Pharmaceuticals Business Launches Dextroamphetamine Sulfate Oral Solution June 20, 2013Tris Pharma Hires President for Generic Pharmaceuticals Business May 2, 2013Tris Pharma’s Ketan Mehta Among Ernst & Young Entrepreneur Of The Year® 2013 Finalists in New Jersey April 3, 2013FDA Approves Tris Pharma’s New Drug Application for KarbinalTM ER (carbinoxamine maleate) Extended-release Oral Suspension March 11, 2013First Product in Tris Pharma’s Collaboration with Vernalis Achieves Proof-of-Concept, Triggering Milestone Payment to Tris January 14, 2013Pfizer Announces Availability Of Quillivant XR™ (methylphenidate hydrochloride) CII For Extended-Release Oral Suspension In The United States October 22, 2012Pfizer To Acquire NextWave Pharmaceuticals, Inc. August 27, 2012Perrigo and Tris Pharma launch store brand version of Delsym® July 11, 2012Tris Pharma Expands Manufacturing Capacity and Strengthens Supply Chain to Support New and Pending Approvals May 31, 2012Tris Pharma Announces Approval of First-Ever Generic to Delsym® Dextromethorphan Polistirex Extended-Release Suspension May 30, 2012Perrigo announces FDA final approval of Tris Pharma’s Dextromethorphan Polistirex extended-release oral Suspension February 6, 2012Vernalis and Tris Pharma announce collaboration to develop and commercialize novel products for the US prescription cough/cold market January 6, 2012Tris Pharma Announces US Patent Grant Covering Platform Technology
